February 10, 2020 11:03 AM ESTUpdated 11:31 AM
R&D
FDA+

Are pri­or­i­ty re­view vouch­er pro­grams stim­u­lat­ing drug de­vel­op­ment? The da­ta sug­gest not re­al­ly, finds GAO re­port

Natalie Grover

Reporter

What is the im­pact of the three pri­or­i­ty re­view vouch­er pro­grams (PRV) on drug de­vel­op­ment? Not much, ac­cord­ing to

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

‭ Regulatory Lead / Head of Regulatory‬

Autonomy Bio Inc.

San Francisco, CA 94107, USA

TRENDING NOW

Trump asks 'very tough hom­bre' Dr. Oz to lead MFN talks

US warns drug­mak­ers against mis­rep­re­sent­ing cost of im­port­ed prod­ucts

About 5% of CBER and CDER left af­ter FDA staff cuts, analy­sis finds

End­points 100 biotech sur­vey: Wel­come to the sum­mer of biotech’s dis­con­tent

An­a­lyz­ing the End­points 100; ‘Most fa­vored na­tion’ tar­gets re­vealed; Biotech slump makes leas­es a li­a­bil­i­ty; and ...

sponsored

Does your sup­ply chain hold up un­der pres­sure for high-risk tem­per­a­ture-crit­i­cal ship­ments?

A service from the Financial Times